Severe Acute Respiratory Syndrome CoronaVirus‐2 (SARS‐CoV‐2) infection can result in different clinical manifestations (COVID-19), from asymptomatic disease to life-threatening respiratory insufficiency.1 Onco-hematologic patients are at higher risk of developing severe COVID-19.2 In particular, patients affected by lymphoproliferative diseases, given the impaired cell-mediated and antibody-mediated immunity and treatment toxicity, more often develop a symptomatic and more serious COVID-19 disease.2-3 Various prophylactic and therapeutic strategies are used against COVID‐19, such as vaccines, antiviral drugs, and S‐protein monoclonal antibodies (anti‐S MoAbs). The efficacy of antiviral strategies often proved to be dependent on SARS-CoV-2 variants.4-6 Pre-exposure prophylaxis with AZD442/Evusheld (tixagevimab-cilgavimab) may be a complementary strategy to decrease the incidence or severity of COVID-19 for patients with hematologic malignancies. Tixagevimab-cilgavimab is a combination of two monoclonal antibodies (T-C MoAb) that bind SARS-CoV-2 spike protein and inhibit the attachment to the surface of cells, preventing viral entry in the cell and COVID-19 development.7,8 In the PROVENT trial, a phase 3 study, 5197 patients were randomized to receive T-C MoAB or placebo, reporting a favorable incidence of only 0.2% of symptomatic COVID-19 in the T-C MoAb arm, even if it included only 3.3% of cancer patients receiving T-C MoAb and was conducted before the Omicron era.8 Based on these findings, T-C MoAB was approved by the Agenzia Italiana del Farmaco (AIFA) as pre-exposure prophylaxis for patients at high risk of severe COVID-19; therefore, it was regularly employed at our institution.9 However, recent studies, mainly performed in vitro, suggested inferior efficacy against omicron variants.10-12 Our aim was to evaluate if this strategy's upcoming reported clinical benefit and safety to patients with hematologic malignancies were still in force in a real-life setting of high-risk hematologic patients during the omicron-predominant COVID-19 wave in Italy

Impact of Sars-CoV-2 Prophylaxis with Tixagevimab-Cilgavimab in High-Risk Patients with B-Cell Malignancies: A Single-Center Retrospective Study / Assanto, Gm; Totaro, M; Poggiali, R; Delli Paoli, A; Annechini, G; D'Elia, Gm; Aji, F; Petrucci, L; Fazio, F; Del Giudice, I; Martelli, M; Micozzi, A; Gentile, G. - In: MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES. - ISSN 2035-3006. - 15:1(2023), pp. 1-5. [10.4084/MJHID.2023.061]

Impact of Sars-CoV-2 Prophylaxis with Tixagevimab-Cilgavimab in High-Risk Patients with B-Cell Malignancies: A Single-Center Retrospective Study

Assanto, GM;Totaro, M;Poggiali, R;Delli Paoli, A;Annechini, G;Aji, F;Petrucci, L;Fazio, F;Del Giudice, I;Martelli, M;Micozzi, A;Gentile, G
2023

Abstract

Severe Acute Respiratory Syndrome CoronaVirus‐2 (SARS‐CoV‐2) infection can result in different clinical manifestations (COVID-19), from asymptomatic disease to life-threatening respiratory insufficiency.1 Onco-hematologic patients are at higher risk of developing severe COVID-19.2 In particular, patients affected by lymphoproliferative diseases, given the impaired cell-mediated and antibody-mediated immunity and treatment toxicity, more often develop a symptomatic and more serious COVID-19 disease.2-3 Various prophylactic and therapeutic strategies are used against COVID‐19, such as vaccines, antiviral drugs, and S‐protein monoclonal antibodies (anti‐S MoAbs). The efficacy of antiviral strategies often proved to be dependent on SARS-CoV-2 variants.4-6 Pre-exposure prophylaxis with AZD442/Evusheld (tixagevimab-cilgavimab) may be a complementary strategy to decrease the incidence or severity of COVID-19 for patients with hematologic malignancies. Tixagevimab-cilgavimab is a combination of two monoclonal antibodies (T-C MoAb) that bind SARS-CoV-2 spike protein and inhibit the attachment to the surface of cells, preventing viral entry in the cell and COVID-19 development.7,8 In the PROVENT trial, a phase 3 study, 5197 patients were randomized to receive T-C MoAB or placebo, reporting a favorable incidence of only 0.2% of symptomatic COVID-19 in the T-C MoAb arm, even if it included only 3.3% of cancer patients receiving T-C MoAb and was conducted before the Omicron era.8 Based on these findings, T-C MoAB was approved by the Agenzia Italiana del Farmaco (AIFA) as pre-exposure prophylaxis for patients at high risk of severe COVID-19; therefore, it was regularly employed at our institution.9 However, recent studies, mainly performed in vitro, suggested inferior efficacy against omicron variants.10-12 Our aim was to evaluate if this strategy's upcoming reported clinical benefit and safety to patients with hematologic malignancies were still in force in a real-life setting of high-risk hematologic patients during the omicron-predominant COVID-19 wave in Italy
2023
COVID-19; Tixagevimab-cilgavimab; B-Cell malignancies; Pre-exposure; Prophylaxis.
01 Pubblicazione su rivista::01a Articolo in rivista
Impact of Sars-CoV-2 Prophylaxis with Tixagevimab-Cilgavimab in High-Risk Patients with B-Cell Malignancies: A Single-Center Retrospective Study / Assanto, Gm; Totaro, M; Poggiali, R; Delli Paoli, A; Annechini, G; D'Elia, Gm; Aji, F; Petrucci, L; Fazio, F; Del Giudice, I; Martelli, M; Micozzi, A; Gentile, G. - In: MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES. - ISSN 2035-3006. - 15:1(2023), pp. 1-5. [10.4084/MJHID.2023.061]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1692100
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact